

Irene Gavras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2239204/publications.pdf>

Version: 2024-02-01

108
papers

4,602
citations

125106

35
h-index

116156

66
g-index

109
all docs

109
docs citations

109
times ranked

2390
citing authors

#	ARTICLE	IF	CITATIONS
1	Blockade of platelet alpha2B-adrenergic receptors: A novel antiaggregant mechanism. International Journal of Cardiology, 2013, 168, 2561-2566.	0.8	12
2	“Volume-expanded”™ hypertension. Journal of Hypertension, 2012, 30, 655-659.	0.3	24
3	A novel bradykinin antagonist with improved properties. Journal of Pharmacy and Pharmacology, 2011, 43, 887-888.	1.2	21
4	Cardioprotective properties of bradykinin: role of the B2 receptor. Hypertension Research, 2010, 33, 772-777.	1.5	43
5	Cardioprotective Effects of a Selective B2 Receptor Agonist of Bradykinin Post-Acute Myocardial Infarct. American Journal of Hypertension, 2010, 23, 562-568.	1.0	42
6	Hypertension in Transgenic Mice With Brain-Selective Overexpression of the $\hat{A}2B$ -Adrenoceptor. American Journal of Hypertension, 2009, 22, 41-45.	1.0	8
7	Angiotensin-Converting Enzyme Inhibition After Experimental Myocardial Infarct. Hypertension, 2008, 51, 1352-1357.	1.3	44
8	Pleiotropic Effects of Statins May Improve Outcomes in Atherosclerotic Renovascular Disease. American Journal of Hypertension, 2008, 21, 1163-1168.	1.0	57
9	Inhibition of the $\hat{A}1D$ -adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors. Vascular Pharmacology, 2007, 46, 367-372.	1.0	5
10	A Novel Gene (Cmya3) Induced in the Heart by Angiotensin II-Dependent but not Salt-Dependent Hypertension in Mice. American Journal of Hypertension, 2006, 19, 275-281.	1.0	17
11	Long-Term Inhibition of the Central $\hat{A}2B$ -Adrenergic Receptor Gene Via Recombinant AAV-Delivered Antisense in Hypertensive Rats. American Journal of Hypertension, 2006, 19, 1135-1143.	1.0	10
12	Frequency of Coronary Artery Disease in Patients With Renal Artery Stenosis Without Clinical Manifestations of Coronary Insufficiency. American Journal of Hypertension, 2006, 19, 1125-1128.	1.0	9
13	Fixed-Drug Combinations as First-Line Treatment for Hypertension. Progress in Cardiovascular Diseases, 2006, 48, 416-425.	1.6	43
14	Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E268-E274.	1.8	41
15	The debate goes on“What is your choice?. American Journal of Cardiology, 2005, 95, 53-54.	0.7	3
16	ACE Inhibitor Trials: Effects in Hypertension. , 2005, , 386-390.		0
17	Angiotensin-converting enzyme regulates bradykinin receptor gene expression. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1814-H1820.	1.5	27
18	Age-related changes of bradykinin B1 and B2 receptors in rat heart. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H202-H205.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. American Journal of Hypertension, 2005, 18, 18-22.	1.0	30
20	Hypertension, vasoactive peptides and coagulation factors. Journal of Hypertension, 2004, 22, 1091-1092.	0.3	7
21	Combination therapy as first-line treatment for hypertension. Current Hypertension Reports, 2004, 6, 267-272.	1.5	26
22	The effect of rapid decreases of blood pressure by different mechanisms on coronary flow and flow reserve in normal coronary arteries. American Journal of Hypertension, 2003, 16, 1000-1005.	1.0	3
23	Mechanisms Mediating the Vasoactive Effects of the B ₁ Receptors of Bradykinin. Hypertension, 2003, 42, 1021-1025.	1.3	30
24	Are Patients Who Develop Angioedema With ACE Inhibition at Risk of the Same Problem With AT ₁ Receptor Blockers?. Archives of Internal Medicine, 2003, 163, 240.	4.3	15
25	Central α ₂ B-adrenergic receptor antisense in plasmid vector prolongs reversal of salt-dependent hypertension. Journal of Hypertension, 2003, 21, 961-967.	0.3	18
26	Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 323-328.	0.6	13
27	Role of vasopressin in 24-hour blood pressure regulation in diabetic patients with autonomic neuropathy. American Journal of Hypertension, 2002, 15, 42-47.	1.0	3
28	Role of α ₂ -adrenergic receptors in hypertension. American Journal of Hypertension, 2001, 14, S171-S177.	1.0	28
29	Is ancient Greek a dead language?. Lancet, The, 2001, 358, 424.	6.3	0
30	Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H1778-H1783.	1.5	39
31	The α ₂ -adrenergic receptors in hypertension and heart failure: experimental and clinical studies. Journal of Hypertension, 2001, 19, 2115-2124.	0.3	231
32	Vasoactive Potential of the B ₁ Bradykinin Receptor in Normotension and Hypertension. Circulation Research, 2001, 88, 275-281.	2.0	134
33	Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 257.	1.5	5
34	Role of the B ₂ Receptor of Bradykinin in Insulin Sensitivity. Hypertension, 2001, 38, 1355-1360.	1.3	85
35	Effects of Antisense Oligodeoxynucleotide Targeting of the α ₂ B-Adrenergic Receptor Messenger RNA in the Central Nervous System. Hypertension, 2001, 38, 1075-1080.	1.3	36
36	The role of ACE inhibition in heart failure. , 2001, , 71-79.		4

#	ARTICLE	IF	CITATIONS
37	Role of the postsynaptic α_2 -adrenergic receptor subtypes in catecholamine-induced vasoconstriction. <i>General Pharmacology</i> , 2000, 34, 101-106.	0.7	49
38	Role of α_2 -Adrenergic Receptor Subtypes in the Acute Hypertensive Response to Hypertonic Saline Infusion in Anephric Mice. <i>Hypertension</i> , 2000, 35, 609-613.	1.3	41
39	Role of the α_2B -Adrenergic Receptor in the Development of Salt-Induced Hypertension. <i>Hypertension</i> , 1999, 33, 14-17.	1.3	105
40	Evidence for Linkage Between Essential Hypertension and a Putative Locus on Human Chromosome 17. <i>Hypertension</i> , 1999, 34, 4-7.	1.3	81
41	The Economics of Therapeutic Advances. <i>Archives of Internal Medicine</i> , 1999, 159, 2634.	4.3	4
42	Sympathoinhibitory Function of the α_2A -Adrenergic Receptor Subtype. <i>Hypertension</i> , 1999, 34, 403-407.	1.3	75
43	Safety and Tolerability of Eprosartan. <i>Pharmacotherapy</i> , 1999, 19, 102S-107S.	1.2	13
44	The Renin-Angiotensin System and the Heart. , 1999, , 53-67.		0
45	Comparison of Spirapril, Isradipine, or Combination in Hypertensive Patients With Left Ventricular Hypertrophy Effects on LVH Regression and Arrhythmogenic Propensity. <i>American Journal of Hypertension</i> , 1998, 11, 640-648.	1.0	18
46	Renal artery clipping attenuates the progression of adriamycin nephropathy. <i>American Journal of Hypertension</i> , 1998, 11, 1124-1128.	1.0	1
47	Autosomal Dominant Orthostatic Hypotensive Disorder Maps to Chromosome 18q. <i>American Journal of Human Genetics</i> , 1998, 63, 1425-1430.	2.6	45
48	Chronic Sympathetic Suppression in the Treatment of Chronic Congestive Heart Failure. <i>Clinical and Experimental Hypertension</i> , 1998, 20, 717-731.	0.5	16
49	Role of Substance P in Blood Pressure Regulation in Salt-Dependent Experimental Hypertension. <i>Hypertension</i> , 1997, 29, 506-509.	1.3	24
50	Combined Sympathetic Suppression and Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure. <i>Hypertension</i> , 1997, 29, 525-530.	1.3	16
51	Role of vasopressin in essential hypertension. <i>Journal of Hypertension</i> , 1997, 15, 545-550.	0.3	93
52	Hemodynamic and Humoral Correlates in Essential Hypertension. <i>Hypertension</i> , 1997, 30, 730-734.	1.3	8
53	Models of Experimental Hypertension in Mice. <i>Hypertension</i> , 1996, 28, 1064-1069.	1.3	132
54	Modern Approaches to Initiating Antihypertensive Therapy. <i>Cardiology Clinics</i> , 1995, 13, 593-598.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Augmentation of Coronary Blood Flow by Ace Inhibition: Role of Angiotensin and Bradykinin. <i>Clinical and Experimental Hypertension</i> , 1995, 17, 1059-1072.	0.5	13
56	Isradipine versus captopril in patients with essential hypertension. <i>Clinical Therapeutics</i> , 1995, 17, 648-654.	1.1	4
57	Role of Bradykinin in Insulin Sensitivity and Blood Pressure Regulation During Hyperinsulinemia. <i>Hypertension</i> , 1995, 25, 1003-1007.	1.3	37
58	Suppressing Sympathetic Activation in Congestive Heart Failure. <i>Hypertension</i> , 1995, 26, 719-724.	1.3	67
59	Cardiovascular Effects of a Specific Nonpeptide Antagonist of Substance P (NK-1) Receptor in DOCA-Salt Hypertension. <i>Hypertension</i> , 1995, 26, 1186-1189.	1.3	2
60	Age and Race Determine Vasopressin Participation in Upright Blood Pressure Control in Essential Hypertension. <i>Annals of the New York Academy of Sciences</i> , 1993, 689, 534-536.	1.8	12
61	ACE Inhibitors: A Decade of Clinical Experience. <i>Hospital Practice (1995)</i> , 1993, 28, 117-127.	0.5	4
62	Bradykinin-mediated effects of ACE inhibition. <i>Kidney International</i> , 1992, 42, 1020-1029.	2.6	112
63	Cardioprotective potential of angiotensin converting enzyme inhibitors. <i>Journal of Hypertension</i> , 1991, 9, 385-392.	0.3	45
64	Effects of bradykinin and prostaglandin inhibition on systemic and regional hemodynamics in conscious normotensive rats. <i>Journal of Hypertension</i> , 1991, 9, 805-812.	0.3	19
65	Angiotensin converting enzyme inhibitors. <i>Journal of Hypertension</i> , 1991, 9, 1075.	0.3	2
66	Cardioprotective potential of angiotensin converting enzyme inhibitors. <i>Clinical Cardiology</i> , 1991, 14, 68-71.	0.7	5
67	Effect of Aging on Vasopressin, Catecholamines, and Alpha ₂ Adrenergic Receptors. <i>Journal of the American Geriatrics Society</i> , 1990, 38, 628-632.	1.3	28
68	Effects of a Novel Renin Inhibitor in Patients with Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1990, 15, 493-500.	0.8	21
69	A new highly potent antagonist of bradykinin. <i>Peptides</i> , 1990, 11, 1041-1043.	1.2	37
70	Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. <i>Journal of Hypertension</i> , 1989, 7, 601-606.	0.3	43
71	Acute Effects of the New Angiotensin Converting Enzyme Inhibitor Cilazapril: A Pilot Study. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 660-663.	1.0	1
72	Renin-angiotensin and vasopressin in the development of salt-induced hypertension. <i>Journal of Hypertension</i> , 1988, 6, 999-1002.	0.3	4

#	ARTICLE	IF	CITATIONS
73	Role of Bradykinin in Hypertension and the Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitors. American Journal of the Medical Sciences, 1988, 295, 305-307.	0.4	19
74	Central Catecholamines and Alpha-Adrenoceptors in Acute Hypertension Induced by Intracerebroventricular Hypertonic Saline. Journal of Hypertension, 1987, 5, 699-704.	0.3	7
75	Stimulation of vasopressin by calcium microinjections in the area of the paraventricular nucleus of the hypothalamus. Brain Research, 1987, 412, 182-184.	1.1	0
76	Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system. American Journal of Medicine, 1987, 83, 20-23.	0.6	15
77	Clinical utility of angiotensin converting enzyme inhibitors in hypertension. American Journal of Medicine, 1986, 81, 28-31.	0.6	5
78	Norepinephrine applied in the paraventricular hypothalamic nucleus stimulates vasopressin release. Brain Research, 1986, 381, 322-326.	1.1	49
79	Calcium Stimulates Vasopressin Release. Journal of Hypertension, 1986, 4, 451-454.	0.3	33
80	Central Alpha-Adrenoceptors During the Development of Hypertension in Rats on High and Low Salt Intake. Journal of Hypertension, 1986, 4, 719-726.	0.3	13
81	Enalaprilat in Hypertensive Emergencies. Journal of Clinical Pharmacology, 1986, 26, 39-43.	1.0	41
82	Nifedipine in the Treatment of Essential Hypertension. Journal of Clinical Pharmacology, 1985, 25, 429-432.	1.0	8
83	Sodium Chloride-induced Partial Inhibition In Vivo Of Alpha2-Adrenoceptor Agonist Function. Journal of Hypertension, 1985, 3, 269-274.	0.3	26
84	Î±-Adrenoceptor agonists applied in the area of the nucleus tractus solitarii in the rat: effect of anesthesia on cardiovascular responses. Brain Research, 1985, 347, 372-375.	1.1	43
85	Hypertensive response to saline microinjection in the area of the nucleus tractus solitarii of the rat. Brain Research, 1985, 343, 113-119.	1.1	18
86	Acute cardiovascular effects of two central phenylethanolamine-N-methyl-transferase inhibitors in unanesthetized desoxycorticosterone-salt hypertensive rats. European Journal of Pharmacology, 1984, 102, 515-519.	1.7	4
87	Evidence for Dopaminergic Regulation of Vasopressin Release in the Anephric Rat. Journal of Hypertension, 1984, 2, 311-316.	0.3	6
88	Salt-induced hypertension in chronic renal failure: Evidence for a neurogenic mechanism. Life Sciences, 1983, 32, 733-740.	2.0	9
89	Systemic and Regional Hemodynamic Effects of Propranolol in Intact and Anephric Rats. Clinical and Experimental Hypertension, 1983, 5, 729-739.	0.3	7
90	Role of Vasoconstrictor Systems in Experimental Glucocorticoid-Hypertension in Rats. Clinical Science, 1983, 65, 255-261.	1.8	26

#	ARTICLE	IF	CITATIONS
91	Captopril and Enalapril. Annals of Internal Medicine, 1983, 98, 556.	2.0	35
92	Antihypertensive Therapy with MK 4211. Journal of Cardiovascular Pharmacology, 1982, 4, 966-972.	0.8	227
93	Prediction of sustained antihypertensive efficacy of chronic captopril therapy: Relationships to immediate blood pressure response and control plasma renin activity. American Heart Journal, 1982, 103, 384-390.	1.2	36
94	ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421".. Lancet, The, 1981, 318, 543-547.	6.3	182
95	Fatal Pancytopenia Associated with the Use of Captopril. Annals of Internal Medicine, 1981, 94, 58.	2.0	56
96	Safety and Efficacy of Chronic Therapy with Captopril in Hypertensive Patients: An Update. Journal of Clinical Pharmacology, 1981, 21, 508-516.	1.0	34
97	Effect of Pindolol on Blood Pressure, Plasma Renin Activity, and Catecholamines in Hypertensive Patients. Journal of Clinical Pharmacology, 1981, 21, 79-83.	1.0	4
98	Position Paper: Vasoconstriction and Volume Factors in Renovascular Hypertension. , 1981, , 159-164.		1
99	The Use of SQ 20,881 Converting Enzyme Inhibitor (Teprotide) for Diagnostic Purposes in Hypertension. , 1980, , 201-210.		0
100	Effect of Nadolol in Treatment of Hypertension. Journal of Clinical Pharmacology, 1979, 19, 137-147.	1.0	15
101	A Comparative Study of the Effects of Oxprenolol Versus Propranolol in Essential Hypertension. Journal of Clinical Pharmacology, 1979, 19, 8-14.	1.0	21
102	Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man. New England Journal of Medicine, 1978, 298, 991-995.	13.9	623
103	Studies on the Activity of the Sympathetic Nervous System in Essential Hypertension. Journal of Human Stress, 1978, 4, 22-28.	0.7	20
104	Effect of Angiotensin Converting Enzyme Inhibition on Blood Pressure, Plasma Renin Activity and Plasma Aldosterone in Essential Hypertension *. Journal of Clinical Endocrinology and Metabolism, 1978, 46, 220-226.	1.8	30
105	Reciprocal Relation between Renin Dependency and Sodium Dependency in Essential Hypertension. New England Journal of Medicine, 1976, 295, 1278-1283.	13.9	119
106	An Angiotensin Converting-Enzyme Inhibitor to Identify and Treat Vasoconstrictor and Volume Factors in Hypertensive Patients. New England Journal of Medicine, 1974, 291, 817-821.	13.9	350
107	HYPOTENSIVE EFFECT OF ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR SQ 20,881. Lancet, The, 1974, 304, 353.	6.3	13
108	Volume factor in low and normal renin essential hypertension. American Journal of Cardiology, 1973, 32, 523-532.	0.7	192